What is SLU-PP-332, and what does a SLU-PP-332 dosage search ask?
SLU-PP-332 is an agonist of the estrogen-related receptors alpha, beta and gamma, nuclear receptors involved in energy metabolism; despite the name, they are not receptors for estrogen [1]. Its developers reported that it activates an acute aerobic exercise program in muscle. It is not a peptide and not an approved medicine.
Searches for slu-pp-332 dosage or slu-pp-332 dose expect a human number. The literature cited here has none: its amounts are given in milligrams per kilogram of mouse body weight, and the one study involving human tissue treated cells in a dish. PinPoint's library does not list the compound, so no half-life input or package example exists for arithmetic [4].
What do the SLU-PP-332 studies report?
A 2024 study gave SLU-PP-332 to diet-induced obese mice and to genetically obese ob/ob mice [1]. Treated mice showed higher energy expenditure and fatty acid oxidation and accumulated less fat mass, and the compound improved insulin sensitivity in the metabolic-syndrome models. The authors concluded that ERR activation may be worth pursuing for obesity, a hypothesis rather than a human finding.
A second 2024 study used SLU-PP-332 and related pan-ERR agonists in mice with heart failure induced by pressure overload [2]. The agonists improved heart pumping function, reduced fibrosis and increased survival, effects the authors linked to higher cardiac fatty acid metabolism and mitochondrial function.
The closest work to people is a 2025 pilot study that took muscle biopsies from 20 women during hip surgery and grew myoblasts from the less active group in culture [3]. Treating those cells with SLU-PP-332 shifted markers of oxidative stress, senescence and differentiation. No participant was given the compound, so the study adds human tissue data without adding any human exposure [3].
Taken together, the three papers describe a mechanism, energy metabolism through the estrogen-related receptors, and consistent effects in mouse models of obesity and heart failure. They do not describe absorption, half-life or tolerability in people, which are the facts any dosing page would need. Several of the papers come from the group that developed the compound [1][2].
| Compound | Status | Half-life input | Package example |
|---|---|---|---|
| SLU-PP-332 | Preclinical research | Not in library | No presentation |
How would SLU-PP-332 be measured and converted?
Arithmetic requires a stated presentation, and none exists: no label, no library entry and no product strength in any source here [4]. Mouse amounts in milligrams per kilogram do not convert to a human figure by multiplying by body weight, because species differ in metabolism and body-surface scaling; this page does not attempt that conversion.
For any product that does state its strength, the logging arithmetic is simple. A capsule entry is milligrams per capsule times count, and a solution entry is amount divided by labeled concentration, then times 100 for U-100 units [5]. The peptide calculator performs the solution step from the values entered.
How do people keep records of research compounds in PinPoint?
PinPoint logs compounds from its library, which spans peptides, metabolic compounds, longevity entries such as NAD+ and 5-Amino-1MQ, and oral, nasal, topical and sublingual routes as well as injection [6][4]. SLU-PP-332 is not among them.
For library compounds, entries record compound, dose, site and pain level, schedules carry reminders, and side effects with severity ratings and daily notes sit beside the dose history [6]. Ask PinPoint can say what published references report about a library compound and never recommends a dose or a change [6].
Get PinPoint on the App StoreWhat do people ask about SLU-PP-332?
- What is SLU-PP-332?
- SLU-PP-332 is a synthetic agonist of the estrogen-related receptors alpha, beta and gamma, described by its developers as an exercise mimetic. It has been studied in mice and in cultured cells.
- Is there a human slu-pp-332 dose?
- No. The cited studies report amounts for mice, and the one study involving human tissue treated cells in culture. No source here gave the compound to people.
- Is SLU-PP-332 a peptide?
- No. It is a small synthetic molecule, not an amino-acid chain.
- Is SLU-PP-332 approved?
- No. It has no approved label or product. It remains a research compound described in mouse and cell studies.
- What does exercise mimetic mean for SLU-PP-332?
- Its developers use the phrase because, in mice, activating the estrogen-related receptors switched on metabolic programs that exercise also activates, such as fatty acid oxidation. It does not mean the compound reproduces exercise in people.
Where do these facts come from?
Sources are listed by kind: labels first, then peer-reviewed papers, then PinPoint's own library, arithmetic and app description. Library values were retrieved from the PinPoint application on 5 October 2026; vendor listings support package sizes only.
- A synthetic ERR agonist and metabolic syndrome in mice, 2024J Pharmacol Exp Ther, 2024. Diet-induced obese and ob/ob mice.Retrieved 2026-10-05 · study
- Pan-ERR agonists in mouse heart failure, 2024Circulation, 2024. Pressure-overload mouse model.Retrieved 2026-10-05 · study
- ERR activation in muscle cells from inactive adults, 2025Front Physiol, 2025. Cultured myoblasts from surgical biopsies; no dosing of people.Retrieved 2026-10-05 · study
- PinPoint compound library, application recordsHalf-life inputs, routes, frequencies, package examples and confidence labels as stored in the iOS app library and mirrored in the peptide guides.Retrieved 2026-10-05 · library
- Unit conversion arithmeticConcentration = amount / volume; volume = amount / concentration; U-100 units = mL x 100; remaining fraction = 2^(-elapsed / half-life).Retrieved 2026-10-05 · arithmetic
- PinPoint App Store descriptionFeature wording from the approved application description, not pricing.Retrieved 2026-10-05 · app-description